From: Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study
IIIA. rs12945597+rs2532105 | |||
---|---|---|---|
Genotype | OR | 95% CI | |
AML/MDS | GG+CC | 1.0 | - |
GG+T- | 1.4 | 0.61–3.0 | |
A-+CC | 1.6 | 0.89–2.8 | |
A-+T- | 2.4 | 1.1–5.4 | |
Malignant melanoma | GG+CC | 1.0 | - |
A-+CC | 1.7 | 0.98–3.0 | |
GG+T- | 2.5 | 1.2–5.2 | |
A-+T- | 2.4 | 1.1–5.4 | |
Bladder cancer | GG+CC | 1.0 | - |
A-+CC | 1.4 | 0.68–2.9 | |
GG+T- | 2.1 | 0.74–6.1 | |
A-+T- | 3.0 | 1.1–7.7 | |
Breast cancer | GG+CC | 1.0 | - |
A-+CC | 1.5 | 0.92–2.6 | |
GG+T- | 2.0 | 1.0–4.1 | |
A-+T- | 3.0 | 1.4–6.4 | |
IIIB. rs1563634b+rs2532105 | |||
Genotype | OR | 95% CI | |
AML/MDS | AA+CC | 1.0 | - |
AA+T- | 0.48 | 0.087–2.7 | |
G-+CC | 1.1 | 0.39–3.1 | |
G-+T- | 1.9 | 0.62–5.8 | |
Malignant melanoma | AA+CC | 1.0 | - |
AA+T- | 0.48 | 0.089–2.6 | |
G-+CC | 1.1 | 0.41–3.1 | |
G-+T- | 2.5 | 0.84–7.4 | |
Bladder cancer | AA+CC | 1.0 | - |
AA+T- | 1.7 | 0.12–23 | |
G-+CC | 3.0 | 0.64–14 | |
G-+T- | 6.5 | 1.3–33 | |
Breast cancer | AA+CC | 1.0 | - |
G-+CC | 2.8 | 1.1–7.2 | |
AA+T- | 12 | 2.1–70 | |
G-+T- | 4.6 | 1.7–13 |